| __timestamp | Eli Lilly and Company | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 305409000 |
| Thursday, January 1, 2015 | 6533000000 | 377080000 |
| Friday, January 1, 2016 | 6452000000 | 432829000 |
| Sunday, January 1, 2017 | 6588100000 | 496079000 |
| Monday, January 1, 2018 | 5975100000 | 557616000 |
| Tuesday, January 1, 2019 | 6213800000 | 658498000 |
| Wednesday, January 1, 2020 | 6121200000 | 770456000 |
| Friday, January 1, 2021 | 6431600000 | 840100000 |
| Saturday, January 1, 2022 | 6440400000 | 944700000 |
| Sunday, January 1, 2023 | 6941200000 | 1136600000 |
| Monday, January 1, 2024 | 8593800000 | 1464300000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic growth. Eli Lilly and Company and Vertex Pharmaceuticals Incorporated, two titans in the field, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Eli Lilly's SG&A expenses have seen a steady increase, peaking at approximately $6.94 billion in 2023, marking a 5% rise from 2014. In contrast, Vertex Pharmaceuticals has demonstrated a more dynamic growth, with SG&A expenses surging by nearly 272% over the same period, reaching around $1.14 billion in 2023. This stark difference highlights Vertex's aggressive expansion strategy compared to Eli Lilly's more stable approach. As these companies navigate the complexities of the pharmaceutical landscape, their spending patterns offer valuable insights into their operational priorities and market strategies.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Bristol-Myers Squibb Company
Eli Lilly and Company or Sanofi: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Eli Lilly and Company and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Eli Lilly and Company vs Veracyte, Inc.
Eli Lilly and Company and Novavax, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Incyte Corporation
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Halozyme Therapeutics, Inc.
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs ADMA Biologics, Inc.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or ImmunityBio, Inc.
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and MorphoSys AG
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Supernus Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Celldex Therapeutics, Inc.